In a report issued on April 20, Andrew Semple from Echelon Wealth Partners maintained a Buy rating on Indiva (NDVAF – Research Report). The company's shares closed last Friday at $0.20, close to its 52-week low of $0.19. According to TipRanks.com, Semple is a 4-star analyst with an average return of 12.8% and a 24.4% success rate. Semple covers the Basic Materials sector, focusing on stocks such as Ascend Wellness Holdings LLC, Green Thumb Industries, and Trulieve Cannabis. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Indiva. See the top stocks recommended by analysts >> Indiva's market cap is currently $25.
https://www.tipranks.com/news/blurbs/echelon-wealth-partners-thinks-indivas-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Indiva (QX) (USOTC:NDVAF)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Indiva (QX) Charts.
Indiva (QX) (USOTC:NDVAF)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Indiva (QX) Charts.